TILT-123 + pembrolizumab

TILT-123 + pembrolizumab is a **combination therapeutic regimen** used in clinical trials for treatment-refractory cancers such as platinum-resistant or refractory ovarian cancer and immune checkpoint inhibitor refractory non-small cell lung cancer[1][2][3]. TILT-123 is a **serotype chimeric oncolytic adenovirus** encoding two immunostimulatory cytokines: **tumor necrosis factor alpha (TNFα)** and **interleukin-2 (IL-2)**, designed to selectively infect and lyse tumor cells while activating and recruiting T-cells to the tumor microenvironment[1][2]. Pembrolizumab is a **monoclonal antibody checkpoint inhibitor** targeting **programmed cell death protein 1 (PD-1)**, blocking the PD-1 pathway to prevent T-cell exhaustion and re-activate immune responses against cancer cells[1][2]. The combination is intended to **synergistically enhance anti-tumor immune responses**: TILT-123 turns immunologically cold tumors hot, while pembrolizumab further amplifies T-cell activity and delays their exhaustion[1][2][4]. TILT-123 is administered intravenously, intratumorally, and/or intraperitoneally; pembrolizumab is given intravenously[1][2]. Clinical trials show the combination is well tolerated with manageable adverse events, and induces significant immune activation and disease control in heavily pre-treated patients[1][2][3][4].

Other names

Ad5/3-E2F-D24-hTNFα-IRES-hIL-2Igrelimogene litadenorepvecKeytruda (for pembrolizumab)